Esperion Therapeutics Inc. (ESPR) Shares Down 2.8%
Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) dropped 2.8% during trading on Monday . The stock traded as low as $10.67 and last traded at $10.85, with a volume of 123,650 shares traded. The stock had previously closed at $11.16.
ESPR has been the subject of several recent analyst reports. WallachBeth Capital downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a research report on Tuesday, July 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective (down previously from $77.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Zacks Investment Research raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. Vetr raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 price objective for the company in a research report on Monday. Finally, Royal Bank Of Canada downgraded shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $25.47.
The firm’s 50-day moving average is $13.69 and its 200 day moving average is $15.58. The company’s market cap is $247.63 million.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.09. On average, equities analysts anticipate that Esperion Therapeutics Inc. will post ($3.57) earnings per share for the current year.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben acquired 7,000 shares of the stock in a transaction that occurred on Wednesday, May 4th. The stock was bought at an average cost of $14.85 per share, for a total transaction of $103,950.00. Following the completion of the transaction, the chief executive officer now owns 41,614 shares of the company’s stock, valued at approximately $617,967.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark E. Mcgovern acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, July 6th. The stock was acquired at an average price of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 600 shares of the company’s stock, valued at approximately $6,000. The disclosure for this purchase can be found here.
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.